Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated…
–$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt…
- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with…
The Phase 2a, proof-of-concept study, called FAST-AA (FArudodstat STudy in Alopecia Areata), will enroll approximately 60 adult patients in the…
WILMINGTON, Del., May 18, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision…
CUPERTINO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage…
Oral presentation features further evaluation of second-generation capsids, demonstrating increased transduction in several brain areas across multiple non-human primate speciesCAMBRIDGE,…
LOS ANGELES, May 18, 2023 (GLOBE NEWSWIRE) -- Diagnosed in 2008 at age 59 with multiple myeloma, Andy Sninsky continues…
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 18, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN),…